Considering that Texprog cells but not terminally exhausted T cells can respond to anti-PD-1 therapy [8], we treated tumor-bearing mice with PD-1 blockade and found that Id2 deletion impaired the generation or maintenance of Slamf6+ Texprog cells that can respond to PD-1 blockade. The gene discussed is PDCD1; the disease is neoplasm.